Author

R. Benhida

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:experimental assay· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. R. Martin· 2 shared C. Favreau· 2 shared G. Robert· 2 shared P. Auberger· 2 shared A. Jacquel· 1 shared A. M. Pendergast· 1 shared A. Porterszman· 1 shared A. Puissant· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

A. R. Martin

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Dual targeting of GPX4 and TXNRD1 triggers eradication of AML cells through induction of apoptosis and ferroptosis

C. Favreau, C. Savy, M. Bourgoin, T. Botton, S. Bailly, F. Granger, C. Birck, M. Zerhouni, E. Kerreneur, A. Vigroux, J. Dussart-Gautheret, M.-L. Arcangeli, T. Cluzeau, A. Porterszman, S. Rocchi, , G. Robert

The paper identifies two compounds that target GPX4 and TXNRD1 to induce apoptosis and ferroptosis in AML cells, effectively eradicating malignant cells while sparing normal hematopoietic cells.

bioRxiv · Apr 3, 2024 · PreprintBiochemistry

MCB-613 exploits a collateral sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer through covalent inhibition of KEAP1

C. F. Bassil, G. R. Anderson, B. Mayro, K. N. Askin, P. S. Winter, S. Gruber, T. M. Hall, J. P. Hoj, C. Cerda-Smith, H. M. Hutchinson, S. T. Killarney, K. R. Singleton, L. Qin, K. Jubien-Girard, C. Favreau, , K. C. Wood

The paper identifies MCB-613 as a compound that targets KEAP1 in EGFR inhibitor-resistant NSCLC cells, exploiting its selective essentiality through covalent inhibition.

bioRxiv · Jan 17, 2023 · PreprintCancer Biology